1458654-31-3

Upstream product

• 27006-02-6 (4-bromo-3,5-dimethylphenyl)methanol 
• 400822-47-1 4-bromo-3,5-dimethylbenzaldehyde 
• 1458654-30-2 4-(4-bromo-3,5-dimethylphenyl)butan-2-ol 
• 1458654-29-9 3-(4-bromo-3,5-dimethylphenyl)propanal 
• 1458654-28-8 3-(4-bromo-3,5-dimethylphenyl)propan-1-ol 
• 4494-84-2 5-allyl-2-bromo-1,3-dimethylbenzene 
• 100189-84-2 2,5-dibromo-1,3-dimethylbenzene 

Downstream Products

• 1458654-33-5 4-(4-bromo-3,5-dimethylphenyl)-2-methylbutan-2-ol 

Relevant academic research and scientific papers

ANTIDIABETIC TRICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds of general formula I, wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS

The present invention relates to compounds of general formula I, (I), wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.